---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-116307"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:55:25.819477+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics appoints Dr. Lee Golden to Board of Directors

## Summary
- Dr. Lee Scott Golden appointed independent Class II director effective Nov 24, 2025; term expires at 2027 annual meeting.
- Golden is EVP and CMO of PTC Therapeutics (PTCT) with 25+ years in cardiovascular and hematologic drug development.
- Golden serves on Science and Technology Committee; receives $35,000 annual fee plus equity awards.
- Appointment aligns with Cadrenal's focus on advancing tecarfarin for anticoagulation unmet needs.

## SEC filing metadata
- accession: 0001213900-25-116307
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390025116307/0001213900-25-116307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390025116307/ea0267189-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-116307
- JSON: https://secwatch.observer/filing/0001213900-25-116307.json
- Plain text: https://secwatch.observer/filing/0001213900-25-116307.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.